We have located links that may give you full text access.
A Lateral-Flow Device for the Rapid Detection of Scedosporium Species.
Diagnostics 2024 April 20
Scedosporium species are human pathogenic fungi, responsible for chronic, localised, and life-threatening disseminated infections in both immunocompetent and immunocompromised individuals. The diagnosis of Scedosporium infections currently relies on non-specific CT, lengthy and insensitive culture from invasive biopsy, and the time-consuming histopathology of tissue samples. At present, there are no rapid antigen tests that detect Scedosporium -specific biomarkers. Here, we report the development of a rapid (30 min) and sensitive (pmol/L sensitivity) lateral-flow device (LFD) test, incorporating a Scedosporium -specific IgG1 monoclonal antibody (mAb), HG12, which binds to extracellular polysaccharide (EPS) antigens between ~15 kDa and 250 kDa secreted during the hyphal growth of the pathogens. The test is compatible with human serum and allows for the detection of the Scedosporium species most frequently reported as agents of human disease ( Scedosporium apiospermum , Scedosporium aurantiacum , and Scedosporium boydii ), with limits of detection (LODs) of the EPS biomarkers in human serum of ~0.81 ng/mL ( S. apiospermum ), ~0.94 ng/mL ( S. aurantiacum ), and ~1.95 ng/mL ( S. boydii ). The Scedosporium -specific LFD ( Sced LFD) test therefore provides a potential novel opportunity for the detection of infections caused by different Scedosporium species.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app